Roche (ROP SW) Q1 2026 (CHF): Sales 14.72bln (prev. 15.44bln Y/Y), Group Sales +6% at constant exchange rates, -5% in CHF, due to significant currency appreciation; confirms 2026 outlook

Roche's Q1 2026 results reflect a 6% increase in group sales at constant exchange rates, although they showed a decline of 5% in CHF due to currency fluctuations.

Newsquawk StaffPublished 23 Apr 2026, 05:25 UTCOn the live feed at 05:05 UTC — 1 more headline followed before this page went public

Newsquawk headlinesUTC

05:29

Newsquawk Daily European Opening News - 23rd April 2026

05:24

Hyundai Motor (005380 KS) Q1 2026 (KRW): Net 2.3tln (exp. 2.5tln), Operating Profit 2.51tln (exp. 2.81tln), Global Market Share 4.9% (prev. 4.6% Q/Q)

05:05

Roche (ROP SW) Q1 2026 (CHF): Sales 14.72bln (prev. 15.44bln Y/Y), Group Sales +6% at constant exchange rates, -5% in CHF, due to significant currency appreciation; confirms 2026 outlook

05:02

Nestle (NESN SW) Q1 2026 (CHF): Sales 21.3bln (exp. 21.1bln), Organic Growth 3.5%; maintains guidance

05:00

Indian HSBC Composite PMI Flash (Apr) 58.30 (Prev. 57.0)

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Try the platform free

Free. No signup, no card.

Sales by Region:

US: 5.69bln (prev. 6.22bln Y/Y)
Europe: 2.23bln (prev. 2.32bln Y/Y)
Japan: 649mln (prev. 671mln Y/Y)

Sales by Unit:

Group: driven by high demand for our innovative medicines and diagnostics.
Pharmaceutical: +7% at CER, -4% in CHF, +10% in USD. Due to continued high growth in sales of medicines for the treatment of severe diseases: Xolair, Phesgo, Hemlibra, Vabysmo & Ocrevus were the top drivers.
Diagnostics: +3% at CER, -7% in CHF, +7% in USD. Demand for core lab and pathology solutions more than offset the impact of healthcare pricing reforms in China.

2026 Outlook:

Confirmed.
Core EPS in the high single-digit range at CER.
Expects to increase dividend in CHF.

Context

The confirmation of their 2026 outlook alongside recent performance suggests resilience in demand for innovative medicines, positioning the company well in a challenging environment. Investors should note the impact of currency on revenue but might view the stable growth in core areas positively.

Equities · last 90 days

Recent headlines that moved markets

EQUITIES/8 Sept · 05:24 UTC

Saudi Energy Minister says a number of energy facilities and utilities were hit; are temporarily halting some operations.

Equity indices, after we published−0.3%

Modest downside seen across equity futures as energy prices tick higher.

EQUITIES/3 Sept · 04:54 UTC

North Korea stripped references to "peaceful unification" with South Korea from the charter of its ruling Workers' Party of Korea, according to Yonhap.

Equity indices, after we published−3.3%

EQUITIES/1 Sept · 16:17 UTC

Initial reports of an American attack on Iran, reports i24's Stein.

ES, after we published−0.2%

EQUITIES/26 Aug · 12:56 UTC

States and Meta (META) and agree to settle claims that platforms harmed children, according to a court filing; Meta agrees to pay a maximum of USD 16.68bln to states as part of deal

Market, after we published+2.6%

EQUITIES/8 Sept · 11:48 UTC

AstraZeneca (AZN LN) says Phase III tozorakimab data in COPD showed a 29%-34% reduction in exacerbations.

Market, after we published+1.0%

EQUITIES/7 Sept · 10:54 UTC

Saudi Aramco Jizan oil facilities were reportedly hit in new strikes, the FT reports citing sources; hit on Monday, damage is being assessed.

Equity indices, after we published−0.1%

Newsquawk Daily

Get both market opens in your inbox.

This note and the other one — the EU open and the US open, every business day, written by the desk. No account needed.

Related headlines

The whole workspace, free to try.

© 2026 Newsquawk. All rights reserved.